Skip to Content
image description
  • image description
  • image description
  • image description

Cancer Clinical Trials

Adjuvant Stage III Colon

CALGB 80702

A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

Breast - Adjuvant

CTSU S1007

Endocrine Therapy +/- Chemo with 1-3 Positive Nodes, Hormone Receptor (+) and Her2 (2) with Recurrence Score (RS) of 25 or Less.

Breast - Adjuvant Node (+) or High Risk Node (-), HER2 Low

NSABP B-47

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.

Breast - Advanced ER (+) HER2 (-)

Pfizer A5481008

A randomized, multicenter, double-blind phase 3 study of PD-0332991 (Oral CDK 4/6 Inhibitor) plus Letrozole versus placebo plus Letrozole for the treatment of postmenopausal women with ER (+), HER2 (-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced disease.

Breast - Advanced ER (+) HER2 (-)

Pfizer A5481023

A randomized, multicenter, double-blind, placebo-controlled phase 3 trial of fulvestrant (Fasdolex®) with or without PD-0332991 (Palbociclib) +/- Goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer whose disease progressed after prior endocrine therapy.

Breast - Bone Pain

Amgen 20110147

Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention with Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim.

Breast - Bone Pain Education

Amgen 20110148

Randomized, Single-Blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim.

Breast - Low or Intermediate Levels of HER2 Protein

PRESENT

A Multicenter, Multinational, Prospective, Randomized, Double-Blind, Controlled Phase 3 Study to Assess the Efficacy and Safety of NeuVaxTM in Subjects with Early Stage NP Breast Cancer whose Tumors Express Low or Intermediate Levels of the HER2 Protein.

Breast - Metastatic, BRCA1 & BRACA2

M12-895

A Randomized Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination with Temozolomide or Veliparib in Combination with Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects with BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer.

Breast Registry

Nipple Sparing

ASBrS Nipple Sparing Mastectomy Registry.

Colorectal - Advanced

Pfizer B2151007

An open-label, multi-center, randomized phase 1B/2 study of PF-05212384 (PI3K inhibitor) plus 5-Fluorouracil-Leucovorin-Iriniotecan (FOLFIRI) versus Bevacizumab plus FOLFIRI in metastatic colorectal cancer.

Genetic Registry

City of Hope Registry

Molecular Genetics Studies of Cancer Patients and Their Relatives

Head and Neck

CTSU E1305

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.

Lung - Advanced / Refractory

Pfizer A7471042

A Phase 2, Multi-Cohort Study to Evaluate the Impact of Prophylactic Intervention on Dermatologic and Gastrointestinal Adverse Events and Patient Reported Outcomes in Patients Treated with Dacomitinib (PF-00299804).

Lung - Metastatic

CTSU S0189

A randomized, phase III study comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without concurrent Cetuximab in patients with advanced non-small cell lung cancer (NSCLC).

Pages

Three Women Photo

Cancer risk assessment, screening and prevention programs are vital to educating people about reducing their chances of developing cancer and assessing the need for intervention. Under the direction of our genetic nurse counselor and the Bienes Cancer Center physicians, our Cancer Risk and Prevention Program is for anyone with cancer or a family history of cancer. The vast majority of participants are women who have or have had breast or ovarian cancer, or are at high risk of developing these two cancers. Click to learn more about Genetic Counseling.

Cancer Resources

More Cancer Resources

®2005-2011 WebMD, LLC. All rights reserved.

WebMD does not provide medical advice, diagnosis or treatment.

See additional information.

Directions

image description